Business Context and Reporting Period
Company: Minerva Neurosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 18, 2019
Reporting Period: Event date September 18, 2019; Signed September 24, 2019.
Context: The Company entered into a Commercial Supply Agreement with Catalent Germany Schorndorf GmbH for the manufacturing and supply of roluperidone tablets (MIN-101).
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It discloses a contractual financial commitment:
- Commitment: Minimum purchase of €1,500,000 (one million, five hundred thousand Euros) per year.
- Duration: Five-year term following the first marketing approval of the drug.
- Cost Structure: The Company must supply the active pharmaceutical ingredient (API) to the manufacturer at no cost.
Material Changes
The primary material change is the execution of the Commercial Supply Agreement with Catalent. This agreement establishes the supply chain for the Company's lead asset, roluperidone, contingent upon regulatory approval. No other material changes to financial position or operations are detailed in this specific filing.
Guidance, Outlook, and Risks
Outlook: The agreement is predicated on the Company receiving its first marketing approval for roluperidone. Manufacturing and supply will commence only after such approval is granted.
Terms and Conditions:
- Extension: The term automatically extends for successive 1-year periods unless 12 months' prior written notice is provided.
- Termination Triggers:
- Uncured material breach by either party.
- Failure to obtain necessary regulatory approval within one year of the agreement's effective date.
- Withdrawal of regulatory approval or cessation of commercialization (with 12 months' notice).
Risks: The agreement is contingent on regulatory success. If approval is not obtained within one year, the agreement may be terminated. The filing does not provide specific risk factors beyond the contractual terms.
Investor Verification Checklist
- Verify the status of the regulatory approval application for roluperidone (MIN-101).
- Confirm the exact effective date of the agreement to calculate the one-year regulatory approval deadline.
- Review the full text of the Commercial Supply Agreement filed as an exhibit to the Form 10-Q for the quarter ended September 30, 2019.
- Assess the Company's cash runway to support the €1,500,000 annual commitment once the drug is approved.